Clinical Trial of Gene Silencing Therapy
June 21, 2022 | Terry Sharrer
From the Cleveland Clinic and collaborating international researchers: “In this phase 1 study of 32 participants with elevated Lp(a) levels and no known cardiovascular disease, the siRNA SLN360 was well tolerated, and a dose-dependent reduction in plasma Lp(a) levels was observed. The findings support further study to determine the safety and efficacy of this siRNA.” MORE
Image Credit: Cleveland Clinic